Aspirin may shield cancer patients from deadly clots during chemo

NCT ID NCT06866964

Recruiting now Prevention Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a daily low-dose aspirin can prevent dangerous blood clots in people with advanced germ cell tumors (including testicular cancer) who are receiving standard chemotherapy. About 35 participants will take aspirin alongside their chemo for 26 weeks. The goal is to see if fewer people develop clots compared to similar patients from past studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

germ cell tumor neoplasm Neoplasms, Germ Cell and Embryonal testicular cancer venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL TUMOR TESTICULAR CANCER

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Charlotte, North Carolina, 28204, United States
Aurora St. Luke's Medical Center MOB
RECRUITING

Milwaukee, Wisconsin, 53215, United States
Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.